vs
杜比实验室（DLB）与Orthofix Medical Inc.（OFIX）财务数据对比。点击上方公司名可切换其他公司
杜比实验室的季度营收约是Orthofix Medical Inc.的1.8倍（$395.6M vs $219.9M），杜比实验室净利率更高（24.0% vs -1.0%，领先25.0%），杜比实验室同比增速更快（7.1% vs 2.0%），过去两年杜比实验室的营收复合增速更高（13.9% vs 8.0%）
杜比实验室是一家美国科技企业，专注于音频降噪、音频编码压缩、空间音频及高动态范围（HDR）影像等技术的研发，旗下技术广泛授权给全球各地的消费电子制造商使用，助力终端产品为用户带来更出色的视听体验。
Orthofix医疗是全球知名骨科医疗器械企业，专注于研发、生产及销售脊柱植入物、骨科创伤产品、骨生长刺激治疗设备及再生医疗产品，服务全球多地的骨科医师与医疗机构，致力于提升肌肉骨骼疾病患者的诊疗效果。
DLB vs OFIX — 直观对比
营收规模更大
DLB
是对方的1.8倍
$219.9M
营收增速更快
DLB
高出5.1%
2.0%
净利率更高
DLB
高出25.0%
-1.0%
两年增速更快
DLB
近两年复合增速
8.0%
损益表 — Q3 FY2026 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $395.6M | $219.9M |
| 净利润 | $94.9M | $-2.2M |
| 毛利率 | 88.7% | 71.1% |
| 营业利润率 | 28.5% | 0.2% |
| 净利率 | 24.0% | -1.0% |
| 营收同比 | 7.1% | 2.0% |
| 净利润同比 | 3.4% | 92.4% |
| 每股收益（稀释后） | $0.99 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DLBOFIX
| Q2 26 | $395.6M | — | ||
| Q1 26 | $346.7M | — | ||
| Q4 25 | $346.7M | $219.9M | ||
| Q3 25 | $307.0M | $205.6M | ||
| Q2 25 | $315.5M | $203.1M | ||
| Q1 25 | $369.6M | $193.6M | ||
| Q4 24 | $357.0M | $215.7M | ||
| Q3 24 | $304.8M | $196.6M |
净利润DLBOFIX
| Q2 26 | $94.9M | — | ||
| Q1 26 | $53.3M | — | ||
| Q4 25 | $53.3M | $-2.2M | ||
| Q3 25 | $49.3M | $-22.8M | ||
| Q2 25 | $46.1M | $-14.1M | ||
| Q1 25 | $91.8M | $-53.1M | ||
| Q4 24 | $67.8M | $-29.1M | ||
| Q3 24 | $58.6M | $-27.4M |
毛利率DLBOFIX
| Q2 26 | 88.7% | — | ||
| Q1 26 | 87.5% | — | ||
| Q4 25 | 87.5% | 71.1% | ||
| Q3 25 | 87.1% | 72.2% | ||
| Q2 25 | 86.1% | 68.7% | ||
| Q1 25 | 90.3% | 62.8% | ||
| Q4 24 | 88.6% | 69.0% | ||
| Q3 24 | 88.8% | 68.7% |
营业利润率DLBOFIX
| Q2 26 | 28.5% | — | ||
| Q1 26 | 17.9% | — | ||
| Q4 25 | 17.9% | 0.2% | ||
| Q3 25 | 9.7% | -8.3% | ||
| Q2 25 | 15.1% | -7.9% | ||
| Q1 25 | 29.2% | -25.2% | ||
| Q4 24 | 22.4% | -5.3% | ||
| Q3 24 | 15.2% | -9.6% |
净利率DLBOFIX
| Q2 26 | 24.0% | — | ||
| Q1 26 | 15.4% | — | ||
| Q4 25 | 15.4% | -1.0% | ||
| Q3 25 | 16.1% | -11.1% | ||
| Q2 25 | 14.6% | -6.9% | ||
| Q1 25 | 24.8% | -27.4% | ||
| Q4 24 | 19.0% | -13.5% | ||
| Q3 24 | 19.2% | -13.9% |
每股收益（稀释后）DLBOFIX
| Q2 26 | $0.99 | — | ||
| Q1 26 | $0.55 | — | ||
| Q4 25 | $0.55 | $-0.05 | ||
| Q3 25 | $0.50 | $-0.57 | ||
| Q2 25 | $0.48 | $-0.36 | ||
| Q1 25 | $0.94 | $-1.35 | ||
| Q4 24 | $0.70 | $-0.76 | ||
| Q3 24 | $0.59 | $-0.71 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $594.7M | $82.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.6B | $450.0M |
| 总资产 | $3.2B | $850.6M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DLBOFIX
| Q2 26 | $594.7M | — | ||
| Q1 26 | $644.6M | — | ||
| Q4 25 | $644.6M | $82.0M | ||
| Q3 25 | $702.6M | $62.9M | ||
| Q2 25 | $699.3M | $65.6M | ||
| Q1 25 | $626.6M | $58.0M | ||
| Q4 24 | $520.8M | $83.2M | ||
| Q3 24 | $482.0M | $30.1M |
总债务DLBOFIX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | $157.2M | ||
| Q2 25 | — | $157.0M | ||
| Q1 25 | — | $156.9M | ||
| Q4 24 | — | $157.0M | ||
| Q3 24 | — | $118.5M |
股东权益DLBOFIX
| Q2 26 | $2.6B | — | ||
| Q1 26 | $2.6B | — | ||
| Q4 25 | $2.6B | $450.0M | ||
| Q3 25 | $2.6B | $442.5M | ||
| Q2 25 | $2.6B | $458.3M | ||
| Q1 25 | $2.6B | $458.3M | ||
| Q4 24 | $2.5B | $503.1M | ||
| Q3 24 | $2.5B | $525.9M |
总资产DLBOFIX
| Q2 26 | $3.2B | — | ||
| Q1 26 | $3.2B | — | ||
| Q4 25 | $3.2B | $850.6M | ||
| Q3 25 | $3.2B | $832.6M | ||
| Q2 25 | $3.2B | $837.2M | ||
| Q1 25 | $3.2B | $823.1M | ||
| Q4 24 | $3.2B | $893.3M | ||
| Q3 24 | $3.1B | $867.9M |
负债/权益比DLBOFIX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.36× | ||
| Q2 25 | — | 0.34× | ||
| Q1 25 | — | 0.34× | ||
| Q4 24 | — | 0.31× | ||
| Q3 24 | — | 0.23× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $147.3M | $27.7M |
| 自由现金流经营现金流 - 资本支出 | — | $16.8M |
| 自由现金流率自由现金流/营收 | — | 7.6% |
| 资本支出强度资本支出/营收 | — | 4.9% |
| 现金转化率经营现金流/净利润 | 1.55× | — |
| 过去12个月自由现金流最近4个季度 | — | $-1.3M |
8季度趋势，按日历期对齐
经营现金流DLBOFIX
| Q2 26 | $147.3M | — | ||
| Q1 26 | $54.8M | — | ||
| Q4 25 | $54.8M | $27.7M | ||
| Q3 25 | $472.2M | $12.4M | ||
| Q2 25 | $67.7M | $11.6M | ||
| Q1 25 | $174.9M | $-18.4M | ||
| Q4 24 | $106.8M | $23.7M | ||
| Q3 24 | $327.3M | $11.7M |
自由现金流DLBOFIX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | $50.2M | $16.8M | ||
| Q3 25 | $435.9M | $2.5M | ||
| Q2 25 | $61.3M | $4.5M | ||
| Q1 25 | $168.0M | $-25.1M | ||
| Q4 24 | $100.0M | $15.2M | ||
| Q3 24 | $297.2M | $6.3M |
自由现金流率DLBOFIX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 14.5% | 7.6% | ||
| Q3 25 | 142.0% | 1.2% | ||
| Q2 25 | 19.4% | 2.2% | ||
| Q1 25 | 45.5% | -13.0% | ||
| Q4 24 | 28.0% | 7.0% | ||
| Q3 24 | 97.5% | 3.2% |
资本支出强度DLBOFIX
| Q2 26 | — | — | ||
| Q1 26 | — | — | ||
| Q4 25 | 1.3% | 4.9% | ||
| Q3 25 | 11.8% | 4.8% | ||
| Q2 25 | 2.0% | 3.5% | ||
| Q1 25 | 1.9% | 3.5% | ||
| Q4 24 | 1.9% | 4.0% | ||
| Q3 24 | 9.8% | 2.7% |
现金转化率DLBOFIX
| Q2 26 | 1.55× | — | ||
| Q1 26 | 1.03× | — | ||
| Q4 25 | 1.03× | — | ||
| Q3 25 | 9.57× | — | ||
| Q2 25 | 1.47× | — | ||
| Q1 25 | 1.91× | — | ||
| Q4 24 | 1.57× | — | ||
| Q3 24 | 5.59× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DLB
| Licensing | $372.2M | 94% |
| Products and services | $23.4M | 6% |
OFIX
| Spinal Implants Biologics And Enabling Technologies | $113.6M | 52% |
| Bone Growth Therapies | $68.3M | 31% |
| Other | $22.7M | 10% |
| IT | $5.9M | 3% |
| GB | $3.5M | 2% |
| FR | $3.5M | 2% |
| DE | $2.3M | 1% |
